Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Poster abstracts of the 18th Pan Arab Cancer Congress. TUNISIA. April 19-21, 2018.

La Tunisie medicale·2018

Same author

Expression of clusterin in colorectal carcinoma in relation to clinicopathological criteria.

The Malaysian journal of pathology·2017

Same author

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2017

Same author

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.

Bladder cancer (Amsterdam, Netherlands)·2016

Same author

Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer.

Anticancer research·2011

Same author

Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer.

Scandinavian journal of gastroenterology·2009

Search research articles

Related Experiment Video

Updated: Jul 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 3, 2013

Prognostic factors in prostate cancer.

A Buhmeida¹, S Pyrhönen, M Laato

¹Departments of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland. abuhme@utu.fi

Diagnostic Pathology

|June 9, 2006

Summary

Gleason score, PSA, and aneuploidy are key indicators for predicting prostate cancer progression and survival. Research highlights these factors for organ-confined and advanced disease, guiding treatment decisions.

Area of Science:

Oncology
Pathology
Urology

Background:

Prognostic factors are crucial for predicting survival and progression in prostate cancer.
Several biomarkers have been investigated for their prognostic significance in different stages of the disease.

Purpose of the Study:

To identify and summarize the most significant prognostic factors for survival and progression in organ-confined, locally advanced, and advanced prostate cancer.

Main Methods:

Review and synthesis of published research on prognostic factors in prostate cancer.
Analysis of biomarkers including Gleason score, tumor volume, surgical margins, Ki-67, p53, PSA, microvessel density, and aneuploidy.

Main Results:

Gleason score, tumor volume, surgical margins, and Ki-67 index are significant for organ-confined disease survival.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 21, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 3, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

PSA, Gleason score, stage, capsular invasion, microvessel density, and aneuploidy are key predictors of progression.

For advanced prostate cancer, Gleason score and nuclear morphometry are highly significant progression predictors.

Conclusions:

Gleason score, capsular invasion, blood PSA, stage, and aneuploidy are the most reliable markers for progression in organ-confined prostate cancer.
While other biological markers show promise, their clinical relevance is still under investigation.
Compound prognostic factors and gene expression profiles offer future potential but require further clinical data.